Ranexa – Mode of action, dosing and side effects
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Related articles
06/27/2016 - Ranolazine for management of microvascular angina - Prof Juan Carlos Kaski, St George's, University of London, UK
06/05/2016 - PPIs associated with endothelial senescence & adverse cardiovascular events - Prof Juan Carlos Kaski, St George's University of London, UK
02/22/2016 - Antibiotic prophylaxis for the prevention of infective endocarditis: should we or shouldn’t we? - Dr Rachel Bastiaenen, PhD, St George's University of London, St George's Hospital London, UK
09/02/2015 - Long QT syndrome and epilepsy -
06/26/2015 - Management of angina and the role of Ranolazine in the context of the NICE guidelines -
06/26/2015 - Clinical cases where an indication for ranolazine may exist - Dr Rajan Sharma, St Geroge's University of London
Leave a Reply
You must be logged in to post a comment.